4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Editas Medicine, Inc. (EDIT) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 87 employees. Its market capitalization is roughly $509 million. In the fiscal year ended 2025-12-31, EDIT reported $40M in revenue and ($160M) in net income.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Interactive charts & full statements → Open the EDIT valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $40M | $32M | $78M | $20M |
| Operating Income (EBIT) | ($99M) | ($239M) | ($169M) | ($226M) |
| Net Income | ($160M) | ($237M) | ($153M) | ($220M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $3M | $25M | $8M | $4M | $5M |
| Operating Income (EBIT) | ($25M) | ($14M) | ($24M) | ($26M) | ($35M) |
| Net Income | ($25M) | ($6M) | ($25M) | ($53M) | ($76M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $186M | $342M | $499M | $514M | — |
| Total Liabilities | $159M | $207M | $150M | $154M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EDIT viewer.
About TickerBase · Data methodology & sources